HeartSciences reports Q1 2025 results and business update in Southlake

Heart Test Laboratories, Inc., known as HeartSciences, announced its financial results for the first quarter of fiscal 2025 on September 12, 2024. The report covered the period ending July 31, 2024, and showcased the company's advancements in its MyoVista wavECG device and the MyoVista Insights cloud-platform. These innovations are designed to enhance the detection of heart disease through artificial intelligence, which is expected to transform traditional ECG practices. During this quarter, HeartSciences made notable progress in developing its AI-ECG solutions, with the MyoVista Insights Platform's Phase 1 version set for completion by the end of 2024. The company is also preparing for FDA 510(k) submission for the MyoVista wavECG device in the first quarter of 2025, following successful patient recruitment and core-lab work for its validation study. The company has received positive feedback on its MyoVista Insights platform, and it is working on integrating licensed algorithms from Mount Sinai. This strategic focus on both cloud-based and device-based solutions is expected to provide HeartSciences with a significant competitive edge in the healthcare sector. Additionally, HeartSciences strengthened its financial position by securing $1.9 million in non-dilutive financing and extending a loan note, ensuring a stable cash runway as it continues to advance its innovative technologies aimed at improving cardiovascular care.